Sodium channel blockers for the treatment of neuropathic pain

被引：0
|
作者：
Anindya Bhattacharya
Alan D. Wickenden
Sandra R. Chaplan
机构：
[1] Johnson & Johnson Pharmaceutical Research & Development,Pain & Related Disorders Team
[2] LLC,undefined
来源：
Neurotherapeutics | 2009年 / 6卷
关键词：
Sodium channel; subtype; selectivity; neuropathic pain; drug discovery;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Drugs that block voltage-gated sodium channels are efficacious in the management of neuropathic pain. Accordingly, this class of ion channels has been a major focus of analgesic research both in academia and in the pharmaceutical/biotechnology industry. In this article, we review the history of the use of sodium channel blockers, describe the current status of sodium channel drug discovery, highlight the challenges and hurdles to attain sodium channel subtype selectivity, and review the potential usefulness of selective sodium channel blockers in neuropathic pain.
引用
收藏
页码：663 / 678
页数：15
相关论文
共 50 条
  • [31] NEUROBIOLOGICAL BASIS FOR SELECTIVITY OF NA+ CHANNEL BLOCKERS IN NEUROPATHIC PAIN
    DEVOR, M
    PAIN FORUM, 1995, 4 (02): : 83 - 86
  • [32] Which intravenous sodium channel blocker for neuropathic pain?
    Chojnowska, E
    ANESTHESIA AND ANALGESIA, 2000, 90 (04): : 1007 - 1008
  • [33] Novel cyclopentane dicarboxamide sodium channel blockers as a potential treatment for chronic pain.
    Shao, PC
    Fisher, MH
    Garcia, ML
    Kaczorowski, GJ
    Lyons, K
    Martin, WJ
    Meinke, PT
    Priest, BT
    Smith, MM
    Wyvratt, MJ
    Ye, F
    Parsons, WH
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U125 - U125
  • [34] Discovery of potent and use-dependent sodium channel blockers for treatment of chronic pain
    Liang, J
    Brochu, RM
    Cohen, CJ
    Dick, IE
    Feiix, JP
    Fisher, MH
    Garcia, ML
    Kaczorowski, GJ
    Lyons, KA
    Meinke, PT
    Priest, BT
    Schmalhofer, WA
    Smith, MM
    Tarpley, JW
    Williams, BS
    Martin, WJ
    Parsons, WH
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (11) : 2943 - 2947
  • [35] NEUROPATHIC PAIN CAN BE RELIEVED BY DRUGS THAT ARE USE-DEPENDENT SODIUM-CHANNEL BLOCKERS - LIDOCAINE, CARBAMAZEPINE, AND MEXILETINE
    TANELIAN, DL
    BROSE, WG
    ANESTHESIOLOGY, 1991, 74 (05) : 949 - 951
  • [36] Discovery and pharmacological evaluation of potent, selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic pain
    Kort, Michael E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [37] Targeting calcium channel blockers for the treatment of pain
    Lee, Chih-Hung
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [38] Reversal of experimental neuropathic pain by T-type calcium channel blockers
    Dogrul, A
    Gardell, LR
    Ossipov, MH
    Tulunay, FC
    Lai, J
    Porreca, F
    PAIN, 2003, 105 (1-2) : 159 - 168
  • [39] Reversal of neuropathic pain by α-hydroxyphenylamide:: A novel sodium channel antagonist
    Ko, Seong-Hoon
    Jochnowitz, Nina
    Lenkowski, Paul W.
    Batts, Timothy W.
    Davis, Gary C.
    Martin, William J.
    Brown, Milton L.
    Patel, Manoj K.
    NEUROPHARMACOLOGY, 2006, 50 (07) : 865 - 873
  • [40] Sodium leak channel contributes to neuronal sensitization in neuropathic pain
    Zhang, Donghang
    Zhao, Wenling
    Liu, Jin
    Ou, Mengchan
    Liang, Peng
    Li, Jia
    Chen, Yali
    Liao, Daqing
    Bai, Siqi
    Shen, Jiefei
    Chen, Xiangdong
    Huang, Han
    Zhou, Cheng
    PROGRESS IN NEUROBIOLOGY, 2021, 202
12345